Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 24;12(1):e0168865.
doi: 10.1371/journal.pone.0168865. eCollection 2017.

Impact of Multidrug Resistance on Tuberculosis Recurrence and Long-Term Outcome in China

Affiliations

Impact of Multidrug Resistance on Tuberculosis Recurrence and Long-Term Outcome in China

Yanni Sun et al. PLoS One. .

Abstract

Little is known about the impact of drug resistance on recurrence in TB. We conducted a cohort study to measure the impact of multi-drug resistance (MDR) on TB recurrence over nine years in Henan Province China. We reviewed medical records and conducted field interviews of 100 MDR and 150 non-MDR TB patients who were treated between 2001 and 2002. We compared long-term recurrence rates, risk factors, and outcomes in 2010 for 234 individuals who could be followed up. About one third (29.5%, 69/234) suffered recurrence after completion of treatment. The overall recurrence rate was 35/1,000 patient-years (PY), with a much higher rate (65/1,000 PY) among MDR-TB patients. MDR (HR: 2.75; CI: 1.58-4.79) and patient annual household income less than 10,000 Yuan (HR: 2.05; CI 1.11-3.80) were associated with recurrence. The mean time for recurrence among MDR-TB patients was 5.7 years, compared to 7.2 years among non-MDR-TB patients. Among the recurrence group members, 61.3% died, and 18.8% had failed treatments. We believe that the high TB recurrence rate after 9 years suggests that a high cure rate cannot accurately predict long-term outcome. We recommend that TB surveillance and control should be strengthened with a focus on MDR-TB and directly observed treatment, to reduce TB recurrence and transmission of MDR-TB.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Selection of the study population in 2010 (reprinted, originally printed @BMC Public Health 2015 [8]).
Fig 2
Fig 2. Geographical location of counties surveyed in Henan Province, 2001 & 2010.
Fig 3
Fig 3. Effect of drug resistance on recurrence over time.

References

    1. Millet J, Orcau A, De Olalla P, Casals M, Rius C and Cayla J, Tuberculosis recurrence and its associated risk factors among successfully treated patients. Journal of Epidemiology and Community Health, 2009. 63(10): p. 799–804 10.1136/jech.2008.077560 - DOI - PubMed
    1. Cox H, Kebede Y, Allamuratova S, Ismailov G, Davletmuratova Z, Byrnes G, et al., Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med, 2006. 3(10): p. e384eng 10.1371/journal.pmed.0030384 - DOI - PMC - PubMed
    1. Vree M, Huong NT, Duong BD, Sy DN, Van LN, Hung NV, et al., Survival and relapse rate of tuberculosis patients who successfully completed treatment in Vietnam. Int J Tuberc Lung Dis, 2007. 11(4): p. 392–7.eng - PubMed
    1. Panjabi R, Comstock GW and Golub JE, Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis, 2007. 11(8): p. 828–37.eng - PubMed
    1. Chiang CY, Enarson DA, Yu MC, Bai KJ, Huang RM, Hsu CJ, et al., Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. European Respiratory Journal, 2006. 28(5): p. 980 10.1183/09031936.06.00125705 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources